Skip to main content

WCLC: Bristol's Opdivo scores again in tough-to-treat mesothelioma, this time flying solo


Last year at the World Conference on Lung Cancer, Bristol Myers Squibb made waves in mesothelioma with data showing its Opdivo-Yervoy duo could slash the risk of death in previously untreated patients. This year, it grabbed the spotlight with another survival win in the tough-to-treat disease.

Saturday, solo Opdivo became the first med to show in a randomized phase 3 trial that it could extend the lives of previously treated mesothelioma patients, cutting their risk of death by 28% against placebo. Those taking Opdivo lived for a median 9.2 months, versus 6.6 months for those in the placebo arm.

Opdivo also staved off disease worsening, slashing the risk of progression or death by 39%. At the one-year mark, 14.5% of Opdivo patients hadn’t seen their cancer worsen, and only 4.9% of placebo patients could say the same.


The results follow on the heels of Opdivo’s performance in first-line mesothelioma from the last WCLC meeting in August. In tandem with Yervoy, BMS’ checkpoint star pared down patients’ risk of death by 26% against chemo, a showing that ultimately earned the pair an FDA green light.

And that’s part of what makes the new data “very exciting,” Sabine Maier, Bristol’s head of oncology clinical development, said.

The trial those new data come from, called Confirm, “falls right in line with what we presented last year,” and it’s “really important” for underscoring Opdivo’s benefit in mesothelioma, she said.

While Opdivo may have demonstrated a benefit in second-line patients, though, BMS is hoping to see most people with mesothelioma treated with the Opdivo-Yervoy pairing upfront.


“I obviously can’t speak to how physicians will make decisions in the clinic, but based on the data we’ve seen, we think this will change the standard of care in the first-line setting,” she said of the Opdivo-Yervoy regimen.

Still, the way BMS sees it, the Confirm data is still important. Having the two data sets “almost back-to-back, within a short time of each other, really demonstrates the value” of BMS’ therapies, Maier said.


https://www.fiercepharma.com/pharma/wclc-bristol-s-opdivo-scores-again-tough-to-treat-mesothelioma-time-flying-solo

 

Comments

Post a Comment

Popular posts from this blog

Pfizer said an updated version of its COVID-19 vaccine will be 'ready in 100 days' if the new Omicron variant is resistant to its current vaccine

  Pfizer said it will be able to manufacture and distribute an updated version of its COVID-19 vaccine within 100 days if the new variant Omicron is found to be resistant to its current vaccine.  Scientists first detected the new variant in South Africa. It has since spread to several other countries, including Israel and Belgium, prompting  a spate of travel restrictions  across Europe, Asia, and  North America , Insider's Aria Bendix  reported . A health official said on Saturday that two cases of the variant have been  detected in the UK . The variant itself has multiple mutations that might make it easier for it to evade antibodies that developed in the body after receiving a COVID-19 vaccine. The mutations might also cause the variant to spread easily —  even among vaccinated people .  The World Health Organization has labeled Omicron a " variant of concern ," a distinction given to the most threatening coronavirus variants. Delta, the v...
Post a Comment
Read more

Texas governor bans vaccine passports from being required in state ABC News

  Thats Right States like Texas and Florida got the Vaccine Passport Conspiracy from Del Bigtree.  https://abc7.com/politics/texas-governor-bans-vaccine-passport-requirement-in-state/10491161/ AUSTIN, Texas -- Gov. Greg Abbott issued an executive order Tuesday morning prohibiting state agencies or political subdivisions in Texas from creating a "vaccine passport" requirement. Conversation has grown around  vaccine passports recently as an option that can be used for travel or even eating out . They are typically described as an app with a code that verifies if someone has been vaccinated or recently tested negative for COVID-19. They're already in use in Israel, and in development in parts of Europe. But Abbott shut that down as an option in the Lone Star State with Executive Order No. GA - 35 also prohibiting "organizations receiving public funds from requiring consumers to provide documentation of vaccine status in order to receive any service or enter any place....
Post a Comment
Read more

Close the Gap Foldit

 
Post a Comment
Read more